Neoadjuvant Toripalimab or Toripalimab in Combination With Carboplatin and Nab-paclitaxel in Untreated HNSCC (HNSCC-002)
Status:
Recruiting
Trial end date:
2027-01-01
Target enrollment:
Participant gender:
Summary
This proposed study will evaluate the efficacy and safety of preoperative administration of
Toripalimab or Toripalimab combined with nab-paclitaxel and carboplatin in Head and Neck
Squamous Cell Carcinoma (HNSCC) who are about to undergo surgery，and it will be helpful for
comprehensive exploratory characterization of tumor immune microenvironment and circulating
immune cells in these patients. Data obtained in this trial will provide valuable information
for planning further prospective clinical trials of anti-PD-1 and other immunotherapies in
HNSCC. We are also eager to identify potential biomarkers of response and toxicity that will
enable patients with HNSCC who are most likely to benefit to receive anti-PD-1 therapy and,
to the contrary, reduce the risk of toxicity and ineffective therapy in patients who are less
likely to benefit from it.
Phase:
Phase 2
Details
Lead Sponsor:
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University